Dr. Oliver Gautschi
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer 2021; 156:91-99.
25.04.2021Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
25.04.2021Lung Cancer 2021; 156:91-99
Froesch Patrizia, Früh Martin, Gautschi Oliver, Sessa Cristiana, König David, Metaxas Yannis, Colombo Ilaria, Schmid Sabine, Oppliger Leibundgut Elisabeth, Rusterholz Corinne, Godar Gilles, Li Qiyu, Rothschild Sacha I, Mark Michael, Swiss Group for Clinical Cancer Research (SAKK)
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
Barbier M, Pardo E, Panje C, Gautschi O, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Eur J Health Econ 2021; 22:669-677.
21.03.2021A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
21.03.2021Eur J Health Econ 2021; 22:669-677
Barbier Michaela Carla, Pardo Esther, Panje Cédric, Gautschi Oliver, Lupatsch Judith Eva, Swiss Group for Clinical Cancer Research (SAKK)
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Britschgi C, Banna G, Wild P, Rothschild S, Gautschi O, Banini M, Metro G, Früh M, Delaloye R, Rechsteiner M, Addeo A, Curioni-Fontecedro A. Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Front Oncol 2020; 10:1299.
21.08.2020Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
21.08.2020Front Oncol 2020; 10:1299
Britschgi Christian, Banna Giuseppe L, Wild Peter J, Rothschild Sacha I, Gautschi Oliver, Banini Marco, Metro Giulio, Früh Martin, Delaloye Raphaël, Rechsteiner Markus, Addeo Alfredo, Curioni-Fontecedro Alessandra
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Molina-Vila M, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Palmero R, Massutí B, Stahel R, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol 2019; 15:416-425.
05.12.2019Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
05.12.2019J Thorac Oncol 2019; 15:416-425
Molina-Vila Miguel-Angel, Ponce Aix Santiago, Carcereny Enric, Früh Martin, Pless Miklos, Popat Sanjay, Cuffe Sinead, Bidoli Paolo, Kammler Roswitha, Roschitzki-Voser Heidi, Tsourti Zoi, Karachaliou Niki, Palmero Ramon, Massutí Bartomeu, Stahel Rolf A, Dafni Urania, Jordana-Ariza Núria, Balada-Bel Ariadna, Garzón-Ibáñez Mónica, García-Peláez Beatriz, Mayo-de-Las-Casas Clara, Felip Enriqueta, Curioni Fontecedro Alessandra, Gautschi Oliver, Peters Solange, Rosell Rafael
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018
26.09.2018Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
26.09.2018J Thorac Oncol 2018
Früh Martin, Guckenberger Matthias, Rothschild Sacha I, Lardinois Didier, Mach Nicholas, Mark Michael, Gautschi Oliver, Thierstein Sandra, Biaggi Rudolf Christine, Weder Walter, Stahel Rolf A, Matzinger Oscar, Betticher Daniel C, Stupp Roger, Xyrafas Alexandros, Peters Solange, Ris Hans Beat, Mirimanoff Rene Olivier, Ochsenbein Adrian F, Schmid Ralph, Pless Miklos
Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrausch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol 2018
21.08.2018Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
21.08.2018J Thorac Oncol 2018
Metaxas Yannis, Froesch Patrizia, Löffler-Baumann Melanie, Pratsch-Peter Susanne, Russell Prudence, Mingrone Walter, Savic Spasenija, Thapa Bibhusal, Früh Martin, Pless Miklos, von Moos Roger, Mauti Laetitia, O'Byrne Kenneth, Petrausch Ulf, Wolleb Sybille, Rivalland Gareth, Klingbiel Dirk, Kao Steven, Schmid Sabine, Nowak Anna K, Gautschi Oliver, Bartnick Tammo, Hughes Brett G, Bouchaab Hasna, Rothschild Sacha, Pavlakis Nick, John Thomas
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)
Panje C, Lupatsch J, Plasswilm L, Aebersold D, Siano M, Gautschi O, Schwenkglenks M, Matter-Walstra K, Dedes K, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiother Oncol 2018; 129:257-263.
10.08.2018A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)
10.08.2018Radiother Oncol 2018; 129:257-263
Panje Cédric, Lupatsch Judith E, Plasswilm Ludwig, Aebersold Daniel M, Siano Marco, Gautschi Oliver, Schwenkglenks Matthias, Matter-Walstra Klazien, Dedes Konstantin J, Swiss Group for Clinical Cancer Research (SAKK)
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay M, Campana M, Gautschi O, Früh M, Fumet J, Audigier-Valette C, Couraud S, Dalle S, Leccia M, Jaffro M, Collot S, Prévot G, Milia J, Pérol M, Dansin E, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot J, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier A, Tomasini P, Mazières J. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017; 50
10.08.2017Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
10.08.2017Eur Respir J. 2017; 50
Delaunay Myriam, Campana Marion, Gautschi Oliver, Früh Martin, Fumet Jean-David, Audigier-Valette Clarisse, Couraud Sébastien, Dalle Stéphane, Leccia Marie-Thérèse, Jaffro Marion, Collot Samia, Prévot Grégoire, Milia Julie, Pérol Maurice, Dansin Eric, Cadranel Jacques, Lusque Amélie, Meyer Nicolas, Gounant Valérie, Moro-Sibilot Denis, Michot Jean-Marie, Raimbourg Judith, Girard Nicolas, Guisier Florian, Planchard David, Metivier Anne-Cécile, Tomasini Pascale, Mazières Julien
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
10.04.2017Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
10.04.2017Lancet Respir Med 2017; 5:435-444
Rosell Rafael, Shah Riyaz, Porta Rut, Majem Margarita, Gómez-Codina Jose, Camps Carlos, Thomas Michael, Rauch Daniel, Barlesi Fabrice, Hanrahan Emer, Kammler Roswitha, Stahel Rolf A, Molina-Vila Miguel A, Shames David S, Tam Rachel, Karachaliou Niki, Kassapian Marie, Rabaglio Manuela, Ruepp Barbara, Coate Linda, Puente Javier, Aix Santiago Ponce, Palmero Ramon, Massutí Bartomeu, Peters Solange, Gautschi Oliver, Curioni-Fontecedro Alessandra, Felip Enriqueta, Dafni Urania, Carcereny Enric, Früh Martin, Reguart Noemí, Froesch Patrizia, Favaretto Adolfo, Bidoli Paolo, Cuffe Sinead, Kotsakis Athanasios, Popat Sanjay, Pless Miklos, BELIEF collaborative group
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Drilon A, Früh M, Diebold J, Zeidler K, Velcheti V, Riess J, Gandara D, Zalcman G, Froesch P, Michels S, Monnet I, Popat S, Mazières J, Cabillic F, Muley T, Warth A, Shih J, Rothschild S, Karachaliou N, Rosell R, Pall G, Ou S, Yang J, Doebele R, Narayanan V, Camidge R, Owen D, Carbone D, Wolf J, Filleron T, Milia J, Besse B, Remon-Masip J, Jänne P, Mok T, Neal J, Wakelee H, Van Den Heuvel M, Karp D, Byoung C, Peled N, Awad M, Gautschi O. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403-1410.
13.03.2017Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
13.03.2017J Clin Oncol 2017; 35:1403-1410
Drilon Alexander, Früh Martin, Diebold Joachim, Zeidler Kristin, Velcheti Vamsidhar, Riess Jonathan W, Gandara David R, Zalcman Gérard, Froesch Patrizia, Michels Sebastian, Monnet Isabelle, Popat Sanjay, Mazières Julien, Cabillic Florian, Muley Thomas, Warth Arne, Shih Jin-Yuan, Rothschild Sacha I, Karachaliou Niki, Rosell Rafael, Pall Georg, Ou Sai-Hong Ignatius, Yang James C H, Doebele Robert C, Narayanan Vignhesh, Camidge Ross, Owen Dwight, Carbone David P, Wolf Juergen, Filleron Thomas, Milia Julie, Besse Benjamin, Remon-Masip Jordi, Jänne Pasi A, Mok Tony S K, Neal Joel W, Wakelee Heather A, Van Den Heuvel Michael, Karp Daniel D, Byoung Chul-Cho, Peled Nir, Awad Mark M, Gautschi Oliver
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Schmid S, Diebold J, Jochum W, Reichegger H, Klingbiel D, Froesch P, Mark M, Rothschild S, Gautschi O, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2016
19.12.2016Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
19.12.2016J Thorac Oncol 2016
Schmid Sabine, Diebold Joachim, Jochum Wolfram, Reichegger Hermann, Klingbiel Dirk, Froesch Patrizia, Mark Michael, Rothschild Sacha, Gautschi Oliver, Früh Martin
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
23.11.2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
23.11.2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.
02.11.2015Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
02.11.2015Lancet Oncol 2015; 16:1651-8
Stahel Rolf A, Caspar Clemens B, Eckhardt Katrin, Schmid Ralph A, Aebersold Daniel M, Gautschi Oliver, Nagel Wolfgang, Töpfer Michael, Krayenbuehl Jerome, Ribi Karin, Ciernik Llja F, Mordasini Carlo, Zippelius Alfred, Riesterer Oliver, Xyrafas Alexandros, Opitz Isabelle, Beyeler Michael, Ochsenbein Adrian, Früh Martin, Cathomas Richard, Nackaerts Kristiaan, Peters Solange, Mamot Christoph, Weder Walter
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
01.10.2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
01.10.2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
11.08.2015Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
11.08.2015Lancet 2015; 386:1049-56
Pless Miklos, Bijelovic Milorad, Ochsenbein Adrian, Meier Urs R, Mamot Christoph, Rauch Daniel, Gautschi Oliver, Betticher Daniel C, Mirimanoff René-Olivier, Peters Solange, Roth Arnaud, Zippelius Alfred, Stupp Roger, Ris Hans-Beat, Stahel Rolf A, Weder Walter, Thierstein Sandra, Gerard Marie-Aline, Xyrafas Alexandros, Früh Martin, Cathomas Richard
The timed up and go test for lumbar degenerative disc disease
Gautschi O, Corniola M, Joswig H, Smoll N, Chau I, Jucker D, Stienen M. The timed up and go test for lumbar degenerative disc disease. Journal of Clinical Neuroscience 2015
07.08.2015The timed up and go test for lumbar degenerative disc disease
07.08.2015Journal of Clinical Neuroscience 2015
Gautschi Oliver, Corniola MV, Joswig Holger, Smoll NR, Chau Ivan, Jucker Dario, Stienen Martin Nikolaus
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
05.03.2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
05.03.2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
10.09.2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
10.09.2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
06.04.2013Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
06.04.2013Eur Urol 2013; 64:150-8
Templeton Arnoud, Schiess Ralph, Wild Peter J, Rüschoff Jan H, Thalmann George, Dietrich Pierre-Yves, Aebersold Ruedi, Klingbiel Dirk, Gillessen Sommer Silke, Müller Beat, Winterhalder Ralph, Stenner Frank, Dutoit Valérie, Cathomas Richard, Rothermundt Christian, Bärtschi Daniela, Dröge Cornelia, Gautschi Oliver, Borner Markus, Fechter Eva, Swiss Group for Clinical Cancer Research (SAKK)
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2012; 79:59-64.
01.11.2012VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
01.11.2012Lung Cancer 2012; 79:59-64
Gautschi Oliver, Stahel Rolf, Carbone David, Na Kyung-Jae, Hsu Schmitz Shu-Fang, Bubendorf Lukas, Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Roder Joanna, Grigorieva Julia, Roder Heinrich, Peters Solange, Crowe Susanne, Dingemans Anne-Marie, Smit Egbert